Genmab has concluded a highly successful first half of 2026, marked by notable financial gains and accelerated progress in its development pipeline. The company achieved a 25% increase in overall revenue, a testament to the growing diversification of its product offerings, with a substantial portion of this growth stemming from innovative non-DARZALEX therapies. This period also saw significant advancements in clinical trials, particularly with positive outcomes for EPCORE DLBCL-4 and the expansion of Petosemtamab into new Phase III studies for colorectal cancer. These strategic moves underscore Genmab’s commitment to advancing its late-stage programs, ensuring capital efficiency, and enhancing shareholder value.
During a recent financial review, Genmab executives highlighted the company's strategic focus on maximizing the commercial potential of its existing medications while simultaneously driving forward its innovative pipeline. The reported increase in full-year revenue guidance to between $4.3 billion and $4.5 billion, reflecting an anticipated growth of 19% for 2026, signals strong market performance. This revised outlook is underpinned by robust sales figures from key products: DARZALEX net trade sales reached $4,207 million, with significant contributions from both the U.S. and international markets. EPKINLY demonstrated exceptional growth, with first-half sales hitting $312 million—a 48% increase year-over-year—driven by enhanced patient enrollment and wider site activations in critical markets like the U.S. and Japan. TIVDAK also contributed positively, achieving $84 million in sales, boosted by expanded site activations across various regions.
The company’s operating profit grew by 18% in the first half of 2026, showcasing Genmab’s capacity to boost profitability while concurrently investing in research and development. An effective tax rate of 3.6% was primarily influenced by the integration of Merus and the strategic use of deferred tax assets, a rate expected to stabilize over the coming 12 to 18 months. The strategic acceleration of late-stage pipeline candidates remains a cornerstone of Genmab's approach. Key data readouts are highly anticipated in the fourth quarter of 2026 for Petosemtamab in head and neck cancer, and for Rina-S in platinum-resistant ovarian cancer, including both Phase II and Phase III trial results. Furthermore, the interim analysis of the EPCORE DLBCL-2 trial for EPKINLY in frontline DLBCL is also expected in Q4 2026, potentially paving the way for new approvals and product launches by 2027.
The successful integration of Merus has been a pivotal element in Genmab’s operational strategy and financial adjustments. Executives emphasized that the sustained expansion of their commercial footprint, coupled with the proven efficacy and safety profiles of their diverse therapeutic portfolio, positions the company for continued long-term growth and market leadership. With a strong focus on high-value clinical programs and disciplined capital management, Genmab is poised to extend its impact in the biotechnology sector well into the next decade.
